up to 40 weeks
This is a parallel group, Phase 3, 2-arm study for treatment. The purpose of this study is to evaluate dupilumab subcutaneous (SC) injections compared to placebo in Chinese adult participants with CRSwNP, on a background therapy with intranasal corticosteroids (budesonide nasal spray).~Study details include:~The study duration will be up to 40 weeks.~The treatment duration will be up to 24 weeks.~The number of visits will be 7.